Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy

Significance Duchenne muscular dystrophy (DMD) is a rare and devastating muscle disease caused by mutations in the X-linked DMD gene (which encodes the dystrophin protein). Serum biomarkers hold significant potential as objective phenotypic measures of DMD disease state, as well as potential measures of pharmacological effects of and response to therapeutic interventions. Here we describe a proteomics approach to determine serum levels of 1,125 proteins in 93 DMD patients and 45 controls. The study identified 44 biomarkers that differed significantly between patients and controls. These data are being made available to DMD researchers and clinicians to accelerate the search for new diagnostic, prognostic, and therapeutic approaches. Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and age-matched healthy volunteers using a modified aptamer-based proteomics technology. Levels of 1,125 proteins were quantified in serum samples from two independent DMD cohorts: cohort 1 (The Parent Project Muscular Dystrophy–Cincinnati Children’s Hospital Medical Center), 42 patients with DMD and 28 age-matched normal volunteers; and cohort 2 (The Cooperative International Neuromuscular Research Group, Duchenne Natural History Study), 51 patients with DMD and 17 age-matched normal volunteers. Forty-four proteins showed significant differences that were consistent in both cohorts when comparing DMD patients and healthy volunteers at a 1% false-discovery rate, a large number of significant protein changes for such a small study. These biomarkers can be classified by known cellular processes and by age-dependent changes in protein concentration. Our findings demonstrate both the utility of this unbiased biomarker discovery approach and suggest potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, we hope, other rare and devastating diseases.

[1]  Daniel O'Connell,et al.  Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets , 2012, Proceedings of the National Academy of Sciences.

[2]  H. Sweeney,et al.  Systemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Normal and Dystrophic Mice , 2010, PloS one.

[3]  B. Wong,et al.  Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal , 2002, Journal of child neurology.

[4]  E. Hoffman,et al.  VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects , 2013, EMBO molecular medicine.

[5]  S. Peltz,et al.  Ataluren as an agent for therapeutic nonsense suppression. , 2013, Annual review of medicine.

[6]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[7]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[8]  E. Lee,et al.  Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse , 2014, Arthritis Research & Therapy.

[9]  Kristy Brown,et al.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.

[10]  B. Lin,et al.  Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders , 2013, Current opinion in supportive and palliative care.

[11]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[12]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[13]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[14]  R. Butowt,et al.  GDNF increases the survival of developing oculomotor neurons through a target-derived mechanism , 2003, Molecular and Cellular Neuroscience.

[15]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[16]  Thomas E. Edwards,et al.  Crystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid Ligand , 2014, The Journal of Biological Chemistry.

[17]  Juan Li,et al.  Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. , 2008, Human gene therapy.

[18]  B. Alman,et al.  The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[19]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[20]  Jay J. Han,et al.  The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used , 2013, Muscle & nerve.

[21]  D. Schneider,et al.  Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor , 2014, The Journal of Biological Chemistry.

[22]  Richard T. Lee,et al.  Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.

[23]  E. Hoffman,et al.  Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. , 2012, Physical medicine and rehabilitation clinics of North America.

[24]  E. Bertini,et al.  Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies , 2014, EMBO molecular medicine.

[25]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[26]  A. Ferlini,et al.  Biomarkers and surrogate endpoints in Duchenne: Meeting report , 2014, Neuromuscular Disorders.

[27]  E. Hoffman,et al.  Phospholipase A2 activity in dystrophinopathies , 1995, Neuromuscular Disorders.

[28]  Nathalie Jette,et al.  A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy , 2014, Neuromuscular Disorders.

[29]  K. Davies,et al.  Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.

[30]  Eric P Hoffman,et al.  Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. , 2013, Discovery medicine.

[31]  Jay J. Han,et al.  The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.

[32]  K. Wagner,et al.  Therapeutic advances in muscular dystrophy , 2013, Annals of neurology.

[33]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.

[34]  J. Mendell,et al.  Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.

[35]  L. Popplewell,et al.  New developments in the use of gene therapy to treat Duchenne muscular dystrophy , 2014, Expert opinion on biological therapy.

[36]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[37]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[38]  Yun‐Sil Lee,et al.  Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2 , 2013, Proceedings of the National Academy of Sciences.

[39]  J. Ervasti,et al.  A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin , 1993, The Journal of cell biology.

[40]  N. Anderson,et al.  The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. , 2010, Clinical chemistry.

[41]  T. Khurana,et al.  Myostatin propeptide‐mediated amelioration of dystrophic pathophysiology , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[42]  Jay J. Han,et al.  The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.

[43]  Larry Gold,et al.  Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents , 2014, Molecular therapy. Nucleic acids.

[44]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .